The landscape of systemic therapy for early stage triple-negative breast cancer

Lu, Juanjuan; Soto, Alvaro Alvarez; Anampa, Jesus

doi:10.1080/14656566.2022.2095902

Cited by 5 publications

(5 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, the management of TNBC that is unresponsive to the current treatment approaches is still a main clinical challenge and for this reason it is important to develop novel therapeutic strategies [ 3 , 50 , 51 , 52 ]. In this study, we demonstrated that zein nanoparticles can be used as biocompatible carriers for the co-delivery of the BET inhibitor JQ1 and PTX, two molecules characterized by a strong lipophilic character [ 4 , 53 ].…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Specific chemotherapy for the treatment of TNBC is currently unavailable [ 3 , 4 ]. Paclitaxel (PTX), a lipophilic chemotherapeutic agent belonging to the taxane family, is an efficacious anticancer agent and is also being used against TNBC in clinical practice [ 3 , 5 ]. Unfortunately, allergic reactions, myelosuppression, and digestive tract reactions are the highly undesirable side effects of PTX, most of them related to the organic solvents used to solubilize the active compound, a fact which has widely compromised its clinical application [ 4 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Co-Encapsulation of Paclitaxel and JQ1 in Zein Nanoparticles as Potential Innovative Nanomedicine

et al. 2022

View full text Add to dashboard Cite

The manuscript describes the development of zein nanoparticles containing paclitaxel (PTX) and the bromo-and extra-terminal domain inhibitor (S)-tertbutyl2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate (JQ1) together with their cytotoxicity on triple-negative breast cancer cells. The rationale of this association is that of exploiting different types of cancer cells as targets in order to obtain increased pharmacological activity with respect to that exerted by the single agents. Zein, a protein found in the endosperm of corn, was used as a biomaterial to obtain multidrug carriers characterized by mean sizes of ˂200 nm, a low polydispersity index (0.1–0.2) and a negative surface charge. An entrapment efficiency of ~35% of both the drugs was obtained when 0.3 mg/mL of the active compounds were used during the nanoprecipitation procedure. No adverse phenomena such as sedimentation, macro-aggregation or flocculation occurred when the nanosystems were heated to 37 °C. The multidrug nanoformulation demonstrated significant in vitro cytototoxic activity against MDA-MB-157 and MDA-MB-231 cancer cells by MTT-test and adhesion assay which was stronger than that of the compounds encapsulated as single agents. The results evidence the potential application of zein nanoparticles containing PTX and JQ1 as a novel nanomedicine.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Co-Encapsulation of Paclitaxel and JQ1 in Zein Nanoparticles as Potential Innovative Nanomedicine

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Targeting these genes using RNA interference technology can efectively inhibit cancer cell proliferation and metastasis, thus achieving therapeutic efects [93]. Te mRNA vaccine immunotherapy is a cuttingedge feld in nanomedicine, where RNA vaccines synthesize mRNA via phage RNA polymerase and in vitro transcription (IVT) of template DNA encoding specifc antigens [94]. A host immune response is produced by the translation of mRNA transcripts into tumor-specifc antigens and their delivery to T cells by antigen-presenting cells.…”

Section: Gene Therapy For Tnbcmentioning

confidence: 99%

Triple-Negative Breast Cancer Treatment Advancements: A Review of Evolving Strategies

Liu,

Zhang,

Huang

2024

European Journal of Cancer Care

View full text Add to dashboard Cite

Women around the world are most frequently afflicted with breast cancer, and it is one of the most frequent causes of cancer death in females. Breast cancer is usually classified according to biomarker status, triple‐negative breast cancer (TNBC) represents a distinct subtype characterized by immunohistochemical findings that denote negativity for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (Her-2) on cancer tissue. It is more common in younger women than in other subtypes. As an invasive breast cancer subtype with a unique drug-resistant phenotype and metastatic burden, it has limited treatment options, and patients have a poor prognosis with high rates of local, distant recurrence and mortality, and there is still a lack of standardized treatment protocols for TNBC. In this review, we delve into the current treatment strategies for TNBC and explore the potential for new approaches and targets in the future. This trial is registered with NCT03997123.

show abstract

“…It generally affects younger women, is more likely to recur, and is associated with a poorer overall survival rate compared with other BC subtypes [ 1 , 2 ]. The term TNBC refers to a heterogeneous group of tumors having different histological, genomic, and immunological characteristics and response to therapy, which have in common the lack of estrogen receptor, progesterone receptor, and epidermal growth factor receptor 2 (HER2); thus, TNBC patients are not eligible for hormone or anti-HER2 therapy [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Aptamer-Based Strategies to Boost Immunotherapy in TNBC

Agnello

d’Argenio

Nilo

et al. 2023

Cancers

View full text Add to dashboard Cite

The immune system (IS) may play a crucial role in preventing tumor development and progression, leading, over the last years, to the development of effective cancer immunotherapies. Nevertheless, immune evasion, the capability of tumors to circumvent destructive host immunity, remains one of the main obstacles to overcome for maximizing treatment success. In this context, promising strategies aimed at reshaping the tumor immune microenvironment and promoting antitumor immunity are rapidly emerging. Triple-negative breast cancer (TNBC), an aggressive breast cancer subtype with poor outcomes, is highly immunogenic, suggesting immunotherapy is a viable strategy. As evidence of this, already, two immunotherapies have recently become the standard of care for patients with PD-L1 expressing tumors, which, however, represent a low percentage of patients, making more active immunotherapeutic approaches necessary. Aptamers are short, highly structured, single-stranded oligonucleotides that bind to their protein targets at high affinity and specificity. They are used for therapeutic purposes in the same way as monoclonal antibodies; thus, various aptamer-based strategies are being actively explored to stimulate the IS’s response against cancer cells. The aim of this review is to discuss the potential of the recently reported aptamer-based approaches to boost the IS to fight TNBC.

show abstract

The landscape of systemic therapy for early stage triple-negative breast cancer

Cited by 5 publications

References 79 publications

Co-Encapsulation of Paclitaxel and JQ1 in Zein Nanoparticles as Potential Innovative Nanomedicine

Co-Encapsulation of Paclitaxel and JQ1 in Zein Nanoparticles as Potential Innovative Nanomedicine

Triple-Negative Breast Cancer Treatment Advancements: A Review of Evolving Strategies

Aptamer-Based Strategies to Boost Immunotherapy in TNBC

Contact Info

Product

Resources

About